440 related articles for article (PubMed ID: 28699490)
1. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
4. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
[TBL] [Abstract][Full Text] [Related]
6. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
[TBL] [Abstract][Full Text] [Related]
7. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors.
Alesawy MS; Al-Karmalawy AA; Elkaeed EB; Alswah M; Belal A; Taghour MS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000237. PubMed ID: 33226150
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440
[TBL] [Abstract][Full Text] [Related]
9. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
Khalifa MM; Al-Karmalawy AA; Elkaeed EB; Nafie MS; Tantawy MA; Eissa IH; Mahdy HA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):299-314. PubMed ID: 34894955
[TBL] [Abstract][Full Text] [Related]
10. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
11. Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators:
Farouk F; Elmaaty AA; Elkamhawy A; Tawfik HO; Alnajjar R; Abourehab MAS; Saleh MA; Eldehna WM; Al-Karmalawy AA
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2171029. PubMed ID: 36701269
[TBL] [Abstract][Full Text] [Related]
12. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues.
Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX
Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885
[TBL] [Abstract][Full Text] [Related]
16. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents.
Alam R; Wahi D; Singh R; Sinha D; Tandon V; Grover A; Rahisuddin
Bioorg Chem; 2016 Dec; 69():77-90. PubMed ID: 27744115
[TBL] [Abstract][Full Text] [Related]
18. Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations.
Elwan A; Sakr H; El-Helby AA; El-Morsy A; Abdelgawad MA; Ghoneim MM; El-Sherbiny M; El-Adl K
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1556-1567. PubMed ID: 35635148
[TBL] [Abstract][Full Text] [Related]
19. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
Nemr MTM; AboulMagd AM
Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel sulfonamide analogues of 6/7-aminoflavones as anticancer agents via topoisomerase II inhibition.
Shelke RN; Pansare DN; Sarkate AP; Narula IK; Lokwani DK; Tiwari SV; Azad R; Thopate SR
Bioorg Med Chem Lett; 2020 Jul; 30(14):127246. PubMed ID: 32527548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
